EE200400078A - Tritsüklilisi 5,6-dihüdro-9H-pürasolo[3,4-c]-1,2,4-triasolo[4,3-alfa]püridiine sisaldavad inhalatsioonikompositsioonid - Google Patents

Tritsüklilisi 5,6-dihüdro-9H-pürasolo[3,4-c]-1,2,4-triasolo[4,3-alfa]püridiine sisaldavad inhalatsioonikompositsioonid

Info

Publication number
EE200400078A
EE200400078A EEP200400078A EEP200400078A EE200400078A EE 200400078 A EE200400078 A EE 200400078A EE P200400078 A EEP200400078 A EE P200400078A EE P200400078 A EEP200400078 A EE P200400078A EE 200400078 A EE200400078 A EE 200400078A
Authority
EE
Estonia
Prior art keywords
triazolo
pyrazolo
pyridines
dihydro
alpha
Prior art date
Application number
EEP200400078A
Other languages
English (en)
Inventor
John Humphrey Michael
Robert Miller Paul
Trevor Shepherd Michael
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200400078A publication Critical patent/EE200400078A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EEP200400078A 2001-09-12 2002-09-02 Tritsüklilisi 5,6-dihüdro-9H-pürasolo[3,4-c]-1,2,4-triasolo[4,3-alfa]püridiine sisaldavad inhalatsioonikompositsioonid EE200400078A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0122031.8A GB0122031D0 (en) 2001-09-12 2001-09-12 Use of pde4 inhibitors in a dry powder inhaler
PCT/IB2002/003599 WO2003022275A1 (en) 2001-09-12 2002-09-02 Inhalation compositions comprising tricyclic 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines

Publications (1)

Publication Number Publication Date
EE200400078A true EE200400078A (et) 2004-06-15

Family

ID=9921954

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400078A EE200400078A (et) 2001-09-12 2002-09-02 Tritsüklilisi 5,6-dihüdro-9H-pürasolo[3,4-c]-1,2,4-triasolo[4,3-alfa]püridiine sisaldavad inhalatsioonikompositsioonid

Country Status (34)

Country Link
US (3) US20030064034A1 (et)
EP (1) EP1427414A1 (et)
JP (1) JP2005505560A (et)
KR (1) KR20040036940A (et)
CN (1) CN1553801A (et)
AP (2) AP2002002623A0 (et)
AR (2) AR036473A1 (et)
BG (1) BG108569A (et)
BR (1) BR0212449A (et)
CA (1) CA2457717A1 (et)
CZ (1) CZ2004310A3 (et)
EA (1) EA006742B1 (et)
EC (1) ECSP045018A (et)
EE (1) EE200400078A (et)
GB (1) GB0122031D0 (et)
HN (2) HN2002000253A (et)
HR (1) HRP20040162A2 (et)
HU (1) HUP0401890A3 (et)
IL (1) IL160380A0 (et)
IS (1) IS7151A (et)
MA (1) MA27062A1 (et)
MX (1) MXPA04002354A (et)
NO (1) NO20041011L (et)
NZ (1) NZ530929A (et)
OA (1) OA12660A (et)
PA (2) PA8554701A1 (et)
PE (2) PE20030443A1 (et)
PL (1) PL368736A1 (et)
SK (1) SK1272004A3 (et)
SV (2) SV2004001227A (et)
TN (1) TNSN04040A1 (et)
TW (1) TW200602054A (et)
WO (2) WO2003022275A1 (et)
ZA (1) ZA200401002B (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7931022B2 (en) 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
AU2003302274A1 (en) * 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
AU2006297037A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd Aerosol powder formulation comprising sieved lactose
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
TR200909788A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
KR20150076005A (ko) 2013-12-26 2015-07-06 삼성디스플레이 주식회사 액정 표시 장치
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
PL3494962T3 (pl) * 2014-09-15 2021-12-06 Verona Pharma Plc Ciekła wziewna kompozycja farmaceutyczna zawierająca RPL554

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004974A (en) * 1995-06-06 1999-12-21 Pfizer Inc Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE19835346A1 (de) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren

Also Published As

Publication number Publication date
TNSN04040A1 (fr) 2006-06-01
WO2003022279A1 (en) 2003-03-20
PE20030443A1 (es) 2003-05-17
KR20040036940A (ko) 2004-05-03
ZA200401002B (en) 2005-02-07
OA12660A (en) 2006-06-19
EP1427414A1 (en) 2004-06-16
HRP20040162A2 (en) 2004-08-31
MXPA04002354A (es) 2004-06-29
PA8554701A1 (es) 2003-09-17
EA200400301A1 (ru) 2004-06-24
PL368736A1 (en) 2005-04-04
NO20041011L (no) 2004-03-10
AR036474A1 (es) 2004-09-08
HN2002000253A (es) 2003-04-07
BG108569A (bg) 2005-02-28
BR0212449A (pt) 2004-08-17
SV2004001226A (es) 2004-02-24
JP2005505560A (ja) 2005-02-24
CN1553801A (zh) 2004-12-08
HN2002000254A (es) 2003-04-07
NZ530929A (en) 2006-08-31
HUP0401890A2 (hu) 2004-12-28
IL160380A0 (en) 2004-07-25
CA2457717A1 (en) 2003-03-20
SK1272004A3 (sk) 2005-03-04
ECSP045018A (es) 2004-04-28
HUP0401890A3 (en) 2008-03-28
PE20030509A1 (es) 2003-06-23
US20030064034A1 (en) 2003-04-03
MA27062A1 (fr) 2004-12-20
GB0122031D0 (en) 2001-10-31
EA006742B1 (ru) 2006-04-28
AP2002002624A0 (en) 2002-09-30
US20030064031A1 (en) 2003-04-03
US20050232871A1 (en) 2005-10-20
SV2004001227A (es) 2004-02-24
AR036473A1 (es) 2004-09-08
IS7151A (is) 2004-02-13
AP2002002623A0 (en) 2002-09-30
PA8554601A1 (es) 2003-09-17
CZ2004310A3 (cs) 2005-02-16
TW200602054A (en) 2006-01-16
WO2003022275A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
IL152869A0 (en) Substituted triazolopyrimidines as anticancer agents
HUP0500109A3 (en) Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
ZA200604960B (en) Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-A]pyrimidin-6-onederivatives
IL172994A0 (en) Substituted tetrahydro-1h-pyrazolo[3,4-c]pyridines, compositions containing them, and use
IL157642A0 (en) Pyrazolopyrimidines as therapeutic agents
IL157640A0 (en) Pyrazolopyrimidines as therapeutic agents
PT1521757E (pt) Espiropiperidinas ou espiropirrolidinas tricíclicas
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
IL156567A0 (en) Triazolopyridines as anti-inflammatory agents
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0401292A3 (en) Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
PT1608653E (pt) Derivados substituídos de 8-perfluoroalquil-6,7,8,9-tetrahidropirimidino ( 1,2-a)pirimidin-4-ona
PT1674456E (pt) Utilização de 2-fluoro-3-cetoésteres para preparar 3-fluoro- 6,7,8,9-tetra-hidro-4-h-pirimido[1,2-a]pirimidin-4-onas
EE200400078A (et) Tritsüklilisi 5,6-dihüdro-9H-pürasolo[3,4-c]-1,2,4-triasolo[4,3-alfa]püridiine sisaldavad inhalatsioonikompositsioonid
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
HUP0500330A3 (en) Heterocondensated tricyclic imidazopyridines, their use and pharmaceutical compositions containing them
IL175724A0 (en) Tricyclic imidazopyridine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EE200100377A (et) Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
PL349364A1 (en) Use of pyridazino[4,5-b
PL366858A1 (en) Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
PL349341A1 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
HUP0303486A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anti-arrythmic compounds agents
MXPA03008894A (es) Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.